Schroder Investment Management Group Has $28.71 Million Holdings in Masimo Co. (MASI)

Schroder Investment Management Group increased its holdings in shares of Masimo Co. (NASDAQ:MASI) by 16.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 338,115 shares of the medical equipment provider’s stock after purchasing an additional 48,300 shares during the quarter. Schroder Investment Management Group owned approximately 0.65% of Masimo worth $28,709,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Prudential Financial Inc. grew its position in shares of Masimo by 14.4% during the second quarter. Prudential Financial Inc. now owns 553,215 shares of the medical equipment provider’s stock worth $50,442,000 after purchasing an additional 69,810 shares in the last quarter. State Street Corp grew its position in shares of Masimo by 10.4% during the second quarter. State Street Corp now owns 1,547,728 shares of the medical equipment provider’s stock worth $141,121,000 after purchasing an additional 146,212 shares in the last quarter. American Century Companies Inc. grew its position in shares of Masimo by 98.0% during the second quarter. American Century Companies Inc. now owns 209,474 shares of the medical equipment provider’s stock worth $19,100,000 after purchasing an additional 103,656 shares in the last quarter. D L Carlson Investment Group Inc. grew its position in shares of Masimo by 32.4% during the second quarter. D L Carlson Investment Group Inc. now owns 46,240 shares of the medical equipment provider’s stock worth $4,216,000 after purchasing an additional 11,315 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. grew its position in shares of Masimo by 27.1% during the second quarter. Robeco Institutional Asset Management B.V. now owns 1,095,353 shares of the medical equipment provider’s stock worth $99,872,000 after purchasing an additional 233,412 shares in the last quarter. Hedge funds and other institutional investors own 83.71% of the company’s stock.

In other news, Director Steven Barker sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $90.00, for a total value of $900,000.00. Following the completion of the sale, the director now directly owns 73,249 shares of the company’s stock, valued at approximately $6,592,410. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Yongsam Lee sold 13,976 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $89.43, for a total value of $1,249,873.68. Following the sale, the executive vice president now directly owns 74,000 shares of the company’s stock, valued at $6,617,820. The disclosure for this sale can be found here. Insiders sold a total of 28,976 shares of company stock valued at $2,599,324 over the last ninety days. Corporate insiders own 16.60% of the company’s stock.

Shares of Masimo Co. (NASDAQ:MASI) opened at $88.88 on Monday. The stock has a market capitalization of $4,592.52, a P/E ratio of 34.05, a PEG ratio of 2.99 and a beta of 0.73. Masimo Co. has a one year low of $60.31 and a one year high of $104.71.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, October 31st. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.53 by $0.17. The business had revenue of $193.69 million during the quarter, compared to analyst estimates of $189.01 million. Masimo had a return on equity of 22.17% and a net margin of 45.83%. The company’s revenue for the quarter was up 15.6% on a year-over-year basis. During the same period last year, the company earned $0.52 EPS. equities analysts predict that Masimo Co. will post 2.95 EPS for the current year.

MASI has been the subject of a number of research reports. BidaskClub lowered Masimo from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Stifel Nicolaus reissued a “buy” rating and set a $108.00 price target on shares of Masimo in a research note on Friday, November 3rd. Zacks Investment Research raised Masimo from a “hold” rating to a “buy” rating and set a $98.00 price target for the company in a research note on Thursday, November 2nd. Finally, BTIG Research raised Masimo from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a research note on Monday, August 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $97.17.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.com-unik.info/2017/12/04/schroder-investment-management-group-has-28-71-million-holdings-in-masimo-co-masi.html.

Masimo Company Profile

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

What are top analysts saying about Masimo Co.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Masimo Co. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit